SCHEMBL19577796

SCHEMBL19577796

B[C@@H]1O[C@H](COCB[C@@H]2O[C@H](COC)C(OP(C)(=O)S)C2O)C(OP(C)(=O)O)C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21202645 0.82 SMPD1 (0.30) —
SCHEMBL21474777 0.82 SMPD1 (0.30) —
SCHEMBL21202641 0.81 FBP1 (0.34) —
SCHEMBL10051004 0.81 FBP1 (0.34) —
SCHEMBL10005831 0.81 FBP1 (0.34) —
SCHEMBL19577795 0.78 — —
SCHEMBL13172425 0.75 FBP1 (0.36) —
SCHEMBL16996706 0.75 FBP1 (0.36) —
SCHEMBL12523685 0.72 SMPD1 (0.41) —
SCHEMBL18892768 0.72 SMPD1 (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213541-B2 Antisense-oligonucleotides as inhibitors of TGF-R signaling Neurovision Pharma GmbH (DE) 2022-01-04 — — US disclosed
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-11-09 — — US disclosed
Send feedback